Nuclear pore glycoprotein-210 (gp210) is an essential trafficking regulator in the eukaryoticnuclear pore complex. Gp-210 anchors the pore complex to the nuclear membrane.[5] and protein tagging reveals its primarily located on the luminal side of double layer membrane at the pore. A single polypeptide motif of gp210 is responsible for sorting to nuclear membrane,[6] and indicate the carboxyl tail of the protein is oriented toward the cytoplasmic side of the membrane.
Duringeukaryoticmitosis thenuclear envelope disintegrates intovesicles dispersingnuclear lamina proteins andnuclear pore complexes. Nup210 is specificallyphosphorylated on the C-terminal (cytoplasmic) domain in mitosis at Ser1880[7] and is dispersed throughout theendoplasmic reticulum during mitosis ashomodimers.[8] Nuclear lamins begin to reassemble around chromosomes at the end of mitosis.[9] Nup210 lags the reassembly process relative to other Nups.[10] and while much of the assembly process can occur without it, the final assembly and dilation of the complexes require Nup210.[11] The replacement ofserine at position 1880 with a phosphorylated 'looking'glutamate results in Nup210 complexes that fail to reassemble indicating thatdephosphorylation of Nup210 within the final phases of proper assembly is required.[12]
Recognized byanti-nuclear antibodies found inprimary biliary cirrhosis (PBC)anti-Nup210 antibodies correlate with progression toward end stage liver disease. Nup210 is possibly a destructive autoimmune target of the disease. One idea for the loss of tolerance is the increased or abnormal expression of Nup210 in patients with PBC.[13]
^Bodoor K, Shaikh S, Salina D, et al. (1999). "Sequential recruitment of NPC proteins to the nuclear periphery at the end of mitosis".J. Cell Sci.112 (13):2253–64.doi:10.1242/jcs.112.13.2253.PMID10362555.
^Onischenko EA, Crafoord E, Hallberg E (2007). "Phosphomimetic mutation of the mitotically phosphorylated serine 1880 compromises the interaction of the transmembrane nucleoporin gp210 with the nuclear pore complex".Exp. Cell Res.313 (12):2744–51.doi:10.1016/j.yexcr.2007.05.011.hdl:10616/41278.PMID17559836.
^Nakamura M, Takii Y, Ito M, et al. (2006). "Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis".J. Autoimmun.26 (2):138–45.doi:10.1016/j.jaut.2005.10.007.PMID16337775.
